Dr. Peter R. Seidensticker, MD - Vice President MCA, Modality Head CT / CV & Informatics - Bayer Pharmaceuticals | LinkedIn
![PDF) Extensive Use of Interventional Therapies Improves Survival in Unresectable or Recurrent Intrahepatic Cholangiocarcinoma PDF) Extensive Use of Interventional Therapies Improves Survival in Unresectable or Recurrent Intrahepatic Cholangiocarcinoma](https://i1.rgstatic.net/publication/293045147_Extensive_Use_of_Interventional_Therapies_Improves_Survival_in_Unresectable_or_Recurrent_Intrahepatic_Cholangiocarcinoma/links/56d83c4608aebe4638b44c71/largepreview.png)
PDF) Extensive Use of Interventional Therapies Improves Survival in Unresectable or Recurrent Intrahepatic Cholangiocarcinoma
![Max SEIDENSTICKER | Senior Physician | Otto-von-Guericke-Universität Magdeburg, Magdeburg | OvGU | Clinic for Radiology and Nuclear Medicine Max SEIDENSTICKER | Senior Physician | Otto-von-Guericke-Universität Magdeburg, Magdeburg | OvGU | Clinic for Radiology and Nuclear Medicine](https://www.researchgate.net/publication/357605597/figure/fig1/AS:1109001827811330@1641418048623/Overall-survival-of-patients-with-compared-to-patients-without-objective-response-CI_Q320.jpg)
Max SEIDENSTICKER | Senior Physician | Otto-von-Guericke-Universität Magdeburg, Magdeburg | OvGU | Clinic for Radiology and Nuclear Medicine
Dr. Peter R. Seidensticker, MD - Vice President MCA, Modality Head CT / CV & Informatics - Bayer Pharmaceuticals | LinkedIn
![PDF) Early tumor shrinkage and response assessment according to mRECIST predict overall survival in hepatocellular carcinoma patients under sorafenib PDF) Early tumor shrinkage and response assessment according to mRECIST predict overall survival in hepatocellular carcinoma patients under sorafenib](https://i1.rgstatic.net/publication/357605597_Early_tumor_shrinkage_and_response_assessment_according_to_mRECIST_predict_overall_survival_in_hepatocellular_carcinoma_patients_under_sorafenib/links/61d60d35e669ee0f5c8a4859/largepreview.png)